Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia

Shira Dinner, Daniel Lee, Michaela Liedtke*

*Corresponding author for this work

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

Despite high rates of complete remission in newly diagnosed adult acute lymphoblastic leukemia (ALL), rates of long-term leukemia-free survival are disappointingly low. Treatment of relapsed disease with chemotherapy, even in patients able to pursue consolidation with allogeneic stem cell transplant, has demonstrated limited success. There are no established standards of care in this setting and few standard treatment options. Novel agents targeting antigens on the lymphoblast cell surface offer unique side effect and anti-leukemic profiles which suggest that their use alone or in combination with chemotherapy may achieve improved outcomes for relapsed or refractory ALL.

Original languageEnglish (US)
Pages (from-to)1715-1724
Number of pages10
JournalLeukemia and Lymphoma
Volume55
Issue number8
DOIs
StatePublished - Jan 1 2014

Keywords

  • Acute lymphoblastic leukemia
  • Immunotherapy
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this